ABIO Annual EBITDA
-$7.30 M
+$3.19 M+30.39%
31 December 2023
Summary:
As of February 5, 2025, ABIO annual earnings before interest, taxes, depreciation & amortization is -$7.30 million, with the most recent change of +$3.19 million (+30.39%) on December 31, 2023. During the last 3 years, it has risen by +$2.35 million (+24.35%).ABIO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABIO Quarterly EBITDA
-$3.11 M
-$647.00 K-26.27%
30 June 2024
Summary:
As of February 5, 2025, ABIO quarterly earnings before interest, taxes, depreciation & amortization is -$3.11 million, with the most recent change of -$647.00 thousand (-26.27%) on June 30, 2024. Over the past year, it has dropped by -$1.54 million (-98.47%).ABIO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABIO TTM EBITDA
-$9.05 M
-$1.17 M-14.80%
30 June 2024
Summary:
As of February 5, 2025, ABIO TTM earnings before interest, taxes, depreciation & amortization is -$9.05 million, with the most recent change of -$1.17 million (-14.80%) on June 30, 2024. Over the past year, it has dropped by -$1.86 million (-25.92%).ABIO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABIO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.4% | -98.5% | -25.9% |
| 3 y3 years | +24.4% | +33.7% | +51.6% |
| 5 y5 years | +8.0% | +33.7% | +51.6% |
ABIO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +70.7% | -111.1% | +432.2% |
ARCA Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$3.11 M(+26.3%) | -$9.05 M(+14.8%) |
| Mar 2024 | - | -$2.46 M(+57.2%) | -$7.88 M(+9.7%) |
| Dec 2023 | -$7.30 M(-30.4%) | -$1.57 M(-17.8%) | -$7.18 M(+0.7%) |
| Sept 2023 | - | -$1.91 M(-1.9%) | -$7.14 M(-8.0%) |
| June 2023 | - | -$1.94 M(+10.0%) | -$7.75 M(-13.8%) |
| Mar 2023 | - | -$1.77 M(+16.3%) | -$9.00 M(-14.1%) |
| Dec 2022 | -$10.48 M(-45.5%) | -$1.52 M(-39.8%) | -$10.48 M(-28.3%) |
| Sept 2022 | - | -$2.52 M(-20.9%) | -$14.62 M(-12.9%) |
| June 2022 | - | -$3.19 M(-1.8%) | -$16.78 M(-8.8%) |
| Mar 2022 | - | -$3.25 M(-42.5%) | -$18.41 M(-4.3%) |
| Dec 2021 | -$19.24 M(+99.5%) | -$5.65 M(+20.5%) | -$19.24 M(+2.9%) |
| Sept 2021 | - | -$4.69 M(-2.7%) | -$18.70 M(+17.1%) |
| June 2021 | - | -$4.82 M(+17.9%) | -$15.97 M(+28.4%) |
| Mar 2021 | - | -$4.08 M(-20.0%) | -$12.44 M(+29.0%) |
| Dec 2020 | -$9.64 M(+73.7%) | -$5.11 M(+160.3%) | -$9.64 M(+67.6%) |
| Sept 2020 | - | -$1.96 M(+53.1%) | -$5.75 M(+15.9%) |
| June 2020 | - | -$1.28 M(-0.7%) | -$4.97 M(-3.0%) |
| Mar 2020 | - | -$1.29 M(+6.0%) | -$5.12 M(-7.8%) |
| Dec 2019 | -$5.55 M(-30.0%) | -$1.22 M(+3.7%) | -$5.55 M(-4.6%) |
| Sept 2019 | - | -$1.18 M(-18.3%) | -$5.82 M(-7.0%) |
| June 2019 | - | -$1.44 M(-16.5%) | -$6.26 M(-9.7%) |
| Mar 2019 | - | -$1.72 M(+16.0%) | -$6.93 M(-12.7%) |
| Dec 2018 | -$7.93 M(-56.4%) | -$1.48 M(-8.2%) | -$7.93 M(-25.4%) |
| Sept 2018 | - | -$1.62 M(-23.3%) | -$10.64 M(-20.3%) |
| June 2018 | - | -$2.11 M(-22.7%) | -$13.36 M(-19.9%) |
| Mar 2018 | - | -$2.73 M(-35.0%) | -$16.68 M(-8.3%) |
| Dec 2017 | -$18.19 M(+11.6%) | -$4.19 M(-3.3%) | -$18.19 M(-0.7%) |
| Sept 2017 | - | -$4.33 M(-20.1%) | -$18.31 M(-1.2%) |
| June 2017 | - | -$5.42 M(+28.0%) | -$18.54 M(+9.4%) |
| Mar 2017 | - | -$4.24 M(-1.8%) | -$16.95 M(+4.0%) |
| Dec 2016 | -$16.29 M(+45.0%) | -$4.32 M(-5.3%) | -$16.29 M(+8.0%) |
| Sept 2016 | - | -$4.56 M(+19.1%) | -$15.08 M(+13.6%) |
| June 2016 | - | -$3.83 M(+6.8%) | -$13.28 M(+9.6%) |
| Mar 2016 | - | -$3.58 M(+15.4%) | -$12.11 M(+7.8%) |
| Dec 2015 | -$11.23 M(+16.1%) | -$3.11 M(+12.9%) | -$11.23 M(+4.7%) |
| Sept 2015 | - | -$2.75 M(+3.3%) | -$10.73 M(+4.6%) |
| June 2015 | - | -$2.67 M(-1.6%) | -$10.26 M(+2.6%) |
| Mar 2015 | - | -$2.71 M(+3.9%) | -$10.00 M(+3.3%) |
| Dec 2014 | -$9.67 M(+40.0%) | -$2.61 M(+14.3%) | -$9.67 M(-3.4%) |
| Sept 2014 | - | -$2.28 M(-5.1%) | -$10.01 M(+5.9%) |
| June 2014 | - | -$2.40 M(+0.7%) | -$9.45 M(+14.7%) |
| Mar 2014 | - | -$2.38 M(-19.0%) | -$8.23 M(+19.2%) |
| Dec 2013 | -$6.91 M(+61.7%) | -$2.94 M(+71.3%) | -$6.91 M(+44.0%) |
| Sept 2013 | - | -$1.72 M(+44.6%) | -$4.80 M(+20.1%) |
| June 2013 | - | -$1.19 M(+12.1%) | -$4.00 M(+1.4%) |
| Mar 2013 | - | -$1.06 M(+27.6%) | -$3.94 M(-7.8%) |
| Dec 2012 | -$4.27 M(-10.2%) | -$831.00 K(-9.3%) | -$4.27 M(-14.4%) |
| Sept 2012 | - | -$916.00 K(-19.2%) | -$4.99 M(-10.4%) |
| June 2012 | - | -$1.13 M(-18.5%) | -$5.57 M(+38.3%) |
| Mar 2012 | - | -$1.39 M(-10.2%) | -$4.03 M(-15.3%) |
| Dec 2011 | -$4.76 M(-41.1%) | -$1.55 M(+3.5%) | -$4.76 M(+0.8%) |
| Sept 2011 | - | -$1.50 M(-465.1%) | -$4.72 M(-10.0%) |
| June 2011 | - | $410.00 K(-119.3%) | -$5.24 M(-33.1%) |
| Mar 2011 | - | -$2.12 M(+40.3%) | -$7.83 M(-3.0%) |
| Dec 2010 | -$8.07 M | -$1.51 M(-25.2%) | -$8.07 M(-45.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$2.02 M(-7.6%) | -$14.94 M(-12.3%) |
| June 2010 | - | -$2.18 M(-7.5%) | -$17.04 M(-26.7%) |
| Mar 2010 | - | -$2.36 M(-71.8%) | -$23.25 M(-24.2%) |
| Dec 2009 | -$10.78 M(-43.4%) | -$8.38 M(+103.2%) | -$30.69 M(+89.8%) |
| Sept 2009 | - | -$4.12 M(-50.9%) | -$16.17 M(-16.7%) |
| June 2009 | - | -$8.39 M(-14.4%) | -$19.40 M(+29.4%) |
| Mar 2009 | - | -$9.80 M(-259.5%) | -$14.99 M(-30.4%) |
| Dec 2008 | -$19.03 M(+33.9%) | $6.14 M(-183.5%) | -$21.54 M(-46.4%) |
| Sept 2008 | - | -$7.35 M(+84.8%) | -$40.16 M(-12.4%) |
| June 2008 | - | -$3.98 M(-75.7%) | -$45.85 M(+228.3%) |
| Mar 2008 | - | -$16.35 M(+31.0%) | -$13.96 M(-1.7%) |
| Dec 2007 | -$14.21 M(-89.7%) | -$12.48 M(-4.4%) | -$14.21 M(-79.9%) |
| Sept 2007 | - | -$13.05 M(-146.8%) | -$70.55 M(-17.4%) |
| June 2007 | - | $27.91 M(-268.2%) | -$85.45 M(-36.0%) |
| Mar 2007 | - | -$16.59 M(-75.9%) | -$133.52 M(-2.8%) |
| Dec 2006 | -$137.39 M(+95.2%) | -$68.81 M(+146.2%) | -$137.39 M(+53.1%) |
| Sept 2006 | - | -$27.95 M(+38.6%) | -$89.75 M(+12.1%) |
| June 2006 | - | -$20.17 M(-1.4%) | -$80.06 M(+4.1%) |
| Mar 2006 | - | -$20.46 M(-3.4%) | -$76.91 M(+9.0%) |
| Dec 2005 | -$70.37 M(+58.0%) | -$21.17 M(+16.0%) | -$70.57 M(+19.1%) |
| Sept 2005 | - | -$18.25 M(+7.2%) | -$59.27 M(+15.6%) |
| June 2005 | - | -$17.02 M(+20.6%) | -$51.29 M(+14.2%) |
| Mar 2005 | - | -$14.12 M(+43.0%) | -$44.89 M(-6.0%) |
| Dec 2004 | -$44.53 M(+12.0%) | -$9.87 M(-3.9%) | -$47.74 M(+10.8%) |
| Sept 2004 | - | -$10.27 M(-3.3%) | -$43.07 M(-0.7%) |
| June 2004 | - | -$10.63 M(-37.3%) | -$43.40 M(-11.1%) |
| Mar 2004 | - | -$16.96 M(+225.8%) | -$48.84 M(+7.8%) |
| Dec 2003 | -$39.76 M(+32.3%) | -$5.21 M(-50.9%) | -$45.28 M(-9.3%) |
| Sept 2003 | - | -$10.60 M(-34.1%) | -$49.91 M(+23.8%) |
| June 2003 | - | -$16.07 M(+19.8%) | -$40.30 M(+28.0%) |
| Mar 2003 | - | -$13.41 M(+36.5%) | -$31.47 M(-14.7%) |
| Dec 2002 | -$30.04 M(-0.8%) | -$9.83 M(+894.7%) | -$36.90 M(-6.5%) |
| Sept 2002 | - | -$988.00 K(-86.4%) | -$39.45 M(-15.6%) |
| June 2002 | - | -$7.24 M(-61.5%) | -$46.72 M(-2.3%) |
| Mar 2002 | - | -$18.84 M(+52.2%) | -$47.82 M(+35.2%) |
| Dec 2001 | -$30.30 M(+54.5%) | -$12.38 M(+49.9%) | -$35.37 M(+19.4%) |
| Sept 2001 | - | -$8.26 M(-1.1%) | -$29.62 M(+15.9%) |
| June 2001 | - | -$8.35 M(+30.7%) | -$25.56 M(+13.4%) |
| Mar 2001 | - | -$6.39 M(-3.6%) | -$22.54 M(-0.8%) |
| Dec 2000 | -$19.61 M(+16.0%) | -$6.63 M(+57.8%) | -$22.73 M(+10.3%) |
| Sept 2000 | - | -$4.20 M(-21.2%) | -$20.60 M(+1.0%) |
| June 2000 | - | -$5.33 M(-18.9%) | -$20.40 M(+5.3%) |
| Mar 2000 | - | -$6.57 M(+46.1%) | -$19.37 M(+13.0%) |
| Dec 1999 | -$16.90 M(-1.2%) | -$4.50 M(+12.5%) | -$17.15 M(+1.8%) |
| Sept 1999 | - | -$4.00 M(-7.0%) | -$16.85 M(-9.2%) |
| June 1999 | - | -$4.30 M(-1.1%) | -$18.55 M(+1.1%) |
| Mar 1999 | - | -$4.35 M(+3.5%) | -$18.35 M(+7.9%) |
| Dec 1998 | -$17.10 M(+147.8%) | -$4.20 M(-26.3%) | -$17.00 M(+14.1%) |
| Sept 1998 | - | -$5.70 M(+39.0%) | -$14.90 M(+36.7%) |
| June 1998 | - | -$4.10 M(+36.7%) | -$10.90 M(+34.6%) |
| Mar 1998 | - | -$3.00 M(+42.9%) | -$8.10 M(+19.1%) |
| Dec 1997 | -$6.90 M(+50.0%) | -$2.10 M(+23.5%) | -$6.80 M(+44.7%) |
| Sept 1997 | - | -$1.70 M(+30.8%) | -$4.70 M(+56.7%) |
| June 1997 | - | -$1.30 M(-23.5%) | -$3.00 M(+76.5%) |
| Mar 1997 | - | -$1.70 M | -$1.70 M |
| Dec 1996 | -$4.60 M | - | - |
FAQ
- What is ARCA biopharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for ARCA biopharma?
- What is ARCA biopharma annual EBITDA year-on-year change?
- What is ARCA biopharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for ARCA biopharma?
- What is ARCA biopharma quarterly EBITDA year-on-year change?
- What is ARCA biopharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for ARCA biopharma?
- What is ARCA biopharma TTM EBITDA year-on-year change?
What is ARCA biopharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ABIO is -$7.30 M
What is the all time high annual EBITDA for ARCA biopharma?
ARCA biopharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.27 M
What is ARCA biopharma annual EBITDA year-on-year change?
Over the past year, ABIO annual earnings before interest, taxes, depreciation & amortization has changed by +$3.19 M (+30.39%)
What is ARCA biopharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ABIO is -$3.11 M
What is the all time high quarterly EBITDA for ARCA biopharma?
ARCA biopharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $27.91 M
What is ARCA biopharma quarterly EBITDA year-on-year change?
Over the past year, ABIO quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.54 M (-98.47%)
What is ARCA biopharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ABIO is -$9.05 M
What is the all time high TTM EBITDA for ARCA biopharma?
ARCA biopharma all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.70 M
What is ARCA biopharma TTM EBITDA year-on-year change?
Over the past year, ABIO TTM earnings before interest, taxes, depreciation & amortization has changed by -$1.86 M (-25.92%)